Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
VERU 
Veru Inc (VERU)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
10/15/2025: VERU (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
5 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $19.75
1 Year Target Price $19.75
| 2 | Strong Buy |
| 2 | Buy |
| 1 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -38.7% | Avg. Invested days 20 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 10/15/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 60.80M USD | Price to earnings Ratio 0.69 | 1Y Target Price 19.75 |
Price to earnings Ratio 0.69 | 1Y Target Price 19.75 | ||
Volume (30-day avg) 5 | Beta -0.74 | 52 Weeks Range 2.64 - 14.20 | Updated Date 10/15/2025 |
52 Weeks Range 2.64 - 14.20 | Updated Date 10/15/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) 6 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -193.71% | Operating Margin (TTM) -227.14% |
Management Effectiveness
Return on Assets (TTM) -52.13% | Return on Equity (TTM) -106.02% |
Valuation
Trailing PE 0.69 | Forward PE 117.65 | Enterprise Value 44794495 | Price to Sales(TTM) 3.6 |
Enterprise Value 44794495 | Price to Sales(TTM) 3.6 | ||
Enterprise Value to Revenue 2.65 | Enterprise Value to EBITDA -3.23 | Shares Outstanding 14650392 | Shares Floating 12570329 |
Shares Outstanding 14650392 | Shares Floating 12570329 | ||
Percent Insiders 14.19 | Percent Institutions 27.57 |
Upturn AI SWOT
Veru Inc
Company Overview
History and Background
Veru Inc., formerly known as Female Health Company, was founded in 1984. Initially focused on women's health, particularly sexual health and contraception, the company has evolved to include cancer and infectious disease therapies. Significant milestones include the launch of the FC2 Female Condom and clinical trial advancements in prostate and breast cancer.
Core Business Areas
- Oncology: Focuses on developing novel therapies for the treatment of prostate and breast cancers. Key product candidate is sabizabulin.
- Infectious Disease: Develops treatments for viral diseases. Former focus on COVID-19. Currently focusing on other infectious diseases.
Leadership and Structure
Mitchell Steiner, M.D., is the Chairman, President, and CEO. The company has a board of directors and various management teams overseeing research and development, clinical operations, commercialization, and finance.
Top Products and Market Share
Key Offerings
- Sabizabulin (Prostate Cancer): An oral microtubule disruptor currently undergoing clinical trials for metastatic castration-resistant prostate cancer (mCRPC). Market potential depends on clinical trial outcomes and regulatory approval. Competitors include Xtandi (enzalutamide) by Astellas Pharma and Pfizer and Zytiga (abiraterone acetate) by Johnson & Johnson.
- FC2 Female Condom: A female condom designed for contraception and prevention of STIs. While market share has declined due to increased competition and changing preferences, it remains a product in the company's portfolio. Competitors include male condoms from companies like Trojan (Church & Dwight) and Durex (Reckitt).
Market Dynamics
Industry Overview
The pharmaceutical industry is highly competitive and subject to extensive regulation. The cancer therapeutics market is driven by an aging population, increasing cancer incidence, and advancements in treatment options. The sexual health market is influenced by public health initiatives, changing consumer preferences, and the availability of various contraceptive methods.
Positioning
Veru is positioned as a specialty pharmaceutical company focused on developing novel therapies for unmet medical needs in oncology and infectious diseases. Its competitive advantage lies in its pipeline of innovative drug candidates and its expertise in developing and commercializing niche products.
Total Addressable Market (TAM)
The total addressable market for prostate cancer therapeutics is estimated to be in the billions of dollars annually. Veru's positioning within this market depends on the clinical success and market adoption of sabizabulin. The infectious disease market also has a large TAM.
Upturn SWOT Analysis
Strengths
- Novel drug candidates in development
- Experienced management team
- Proprietary technology platform
- Focus on unmet medical needs
Weaknesses
- Dependence on clinical trial outcomes
- Limited financial resources compared to larger pharmaceutical companies
- High regulatory risk
- Historical reliance on a single product (FC2 Female Condom)
Opportunities
- Successful clinical trial results leading to regulatory approval
- Partnerships with larger pharmaceutical companies
- Expansion into new therapeutic areas
- Increased awareness and adoption of novel therapies
Threats
- Clinical trial failures
- Regulatory delays or rejections
- Competition from established pharmaceutical companies
- Changes in reimbursement policies
Competitors and Market Share
Key Competitors
- JNJ
- PFE
- BMY
- MRK
Competitive Landscape
Veru faces intense competition from larger, well-established pharmaceutical companies with greater financial resources and broader product portfolios. Its success depends on differentiating its products through superior efficacy, safety, or convenience.
Growth Trajectory and Initiatives
Historical Growth: Historically, Veru's growth has been driven by sales of the FC2 Female Condom and clinical trial advancements. However, reliance on a single product has posed challenges.
Future Projections: Future growth is highly dependent on the success of sabizabulin and other pipeline candidates. Analyst estimates vary widely depending on the perceived probability of success.
Recent Initiatives: Recent initiatives include advancing sabizabulin through clinical trials, seeking regulatory approval for prostate cancer treatment, and exploring partnerships for commercialization.
Summary
Veru Inc. is a pharmaceutical company focused on oncology and infectious diseases, primarily known for its prostate cancer drug candidate, Sabizabulin. The company's future is heavily dependent on the success of its clinical trials. While the company has innovative products, it faces strong competition and has limited financial resources. Successful regulatory approval and partnerships are crucial for Veru's growth.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company press releases
- SEC filings
- Analyst reports
- Industry publications
Disclaimers:
This analysis is based on publicly available information and is not financial advice. Investment decisions should be made after consulting with a qualified financial advisor. Market share data is estimated and may not be precise. Forward-looking statements are subject to risks and uncertainties.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Veru Inc
Exchange NASDAQ | Headquaters Miami, FL, United States | ||
IPO Launch date 1990-07-19 | Chairman, President & CEO Dr. Mitchell S. Steiner F.A.C.S., M.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 210 | Website https://verupharma.com |
Full time employees 210 | Website https://verupharma.com | ||
Veru Inc., a late clinical stage biopharmaceutical company, focuses on developing medicines for treatment of metabolic diseases, oncology, and viral-induced acute respiratory distress syndrome (ARDS). Its marketed products comprise FC2 female condom for the dual protection against unplanned pregnancy and the transmission of sexually transmitted infections. The company's development program includes enobosarm, a selective androgen receptor modulator for treatment of augment fat loss and to prevent muscle loss in sarcopenic obese and overweight elderly patients; Enobosarm, an oral selective androgen receptor modulator for the treatment of AR+ ER+ HER2- metastatic breast cancer; and sabizabulin, a microtubule disruptor for the treatment of hospitalized patients with viral lung infection at high risk for viral induced ARDS and death. The company was formerly known as The Female Health Company and changed its name to Veru Inc. in July 2017. Veru Inc. was incorporated in 1971 and is headquartered in Miami, Florida.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.